Crewe Advisors LLC Astrazeneca PLC Transaction History

Crewe Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	BUY	$66.81 - $80.83 $14,230 - $17,216	213 Added 10.88%	2,170 $169,000
Q1 2024 May 13, 2024	BUY	$61.03 - $69.57 $119,435 - $136,148	1,957 New	1,957 $132,000
Q2 2023 Jul 28, 2023	SELL	$69.91 - $75.81 $38,450 - $41,695	-550 Reduced 22.27%	1,920 $137,000
Q1 2023 May 12, 2023	SELL	$63.15 - $71.6 $8,146 - $9,236	-129 Reduced 4.96%	2,470 $171,000
Q3 2022 Nov 14, 2022	BUY	$53.02 - $135.75 $9,278 - $23,756	175 Added 7.22%	2,599 $143,000
Q2 2022 Aug 02, 2022	BUY	$59.26 - $71.14 $32,593 - $39,127	550 Added 29.35%	2,424 $160,000
Q2 2021 Aug 11, 2021	SELL	$48.42 - $60.18 $12,347 - $15,345	-255 Reduced 11.98%	1,874 $112,000
Q1 2021 Apr 21, 2021	BUY	$47.16 - $54.44 $235 - $272	5 Added 0.24%	2,129 $106,000
Q4 2020 Jan 27, 2021	BUY	$48.52 - $58.02 $98,641 - $117,954	2,033 Added 2234.07%	2,124 $106,000
Q3 2020 Oct 13, 2020	BUY	$53.07 - $61.1 $4,829 - $5,560	91 New	91 $5,000

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $200B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Crewe Advisors LLC with notifications on news.